Özkan Sadullah, Aksan Alperen, Fıratlıgil Fahri B, Kurt Dilara, Sucu Serap, Coşkun Aslıhan, Yücel Kadriye Yakut, Çağlar A Turhan, Üstün Yaprak Engin
Division of Perinatology, Department of Obstetrics and Gynecology, Ankara Etlik City Hospital, Ankara, Turkey.
Department of Obstetrics and Gynecology, Ankara Etlik Zubeyde Hanim Women's Health Education and Research Hospital, Ankara, Turkey.
Placenta. 2025 Jan;159:140-145. doi: 10.1016/j.placenta.2024.12.012. Epub 2024 Dec 19.
Preeclampsia is a serious pregnancy complication requiring early detection to improve outcomes. Profilin-1 (PFN1), linked to vascular dysfunction, may serve as a biomarker for diagnosing preeclampsia and predicting adverse neonatal outcomes. The aim of this study was to determine the serum Profilin-1 levels in patients diagnosed with preeclampsia and to investigate its association with disease severity and adverse neonatal outcomes.
A prospective cross-sectional study was conducted at Etlik City Hospital involving 40 women with preeclampsia and 40 healthy controls. Serum PFN1 levels were measured by ELISA and results were compared between groups. The results were compared between the groups. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic performance of PFN1.
Serum PFN1 levels were significantly higher in the preeclampsia group compared to controls (46.48 [30.23-60.29] vs. 26.41 [19.65-41.76], p < 0.001). The ROC curve showed good diagnostic accuracy for PFN1 in detecting preeclampsia with an AUC of 0.741 (95 % CI: 0.631-0.832, p < 0.001), a sensitivity of 95 % and a specificity of 42.5 %. PFN1 levels were also associated with composite neonatal outcomes, with an AUC of 0.622 (95 % CI: 0.520-0.716, p = 0.042).
PFN1 is a potential biomarker for the diagnosis of preeclampsia. However, further studies are needed to validate its role in predicting adverse neonatal outcomes and to improve its specificity for clinical use.
子痫前期是一种严重的妊娠并发症，需要早期检测以改善结局。与血管功能障碍相关的丝切蛋白-1（PFN1）可能作为诊断子痫前期和预测不良新生儿结局的生物标志物。本研究的目的是确定诊断为子痫前期患者的血清丝切蛋白-1水平，并研究其与疾病严重程度和不良新生儿结局的关系。
在埃特利克市医院进行了一项前瞻性横断面研究，纳入40例子痫前期妇女和40例健康对照。采用酶联免疫吸附测定法（ELISA）测量血清PFN1水平，并在组间进行结果比较。使用受试者工作特征（ROC）曲线评估PFN1的诊断性能。
子痫前期组血清PFN1水平显著高于对照组（46.48 [30.23 - 60.29] 对 26.41 [19.65 - 41.76]，p < 0.001）。ROC曲线显示PFN1在检测子痫前期方面具有良好的诊断准确性，曲线下面积（AUC）为0.741（95%可信区间：0.631 - 0.832，p < 0.001），敏感性为95%，特异性为42.5%。PFN1水平也与综合新生儿结局相关，AUC为0.622（95%可信区间：0.520 - 0.716，p = 0.042）。
PFN1是子痫前期诊断的潜在生物标志物。然而，需要进一步研究来验证其在预测不良新生儿结局中的作用，并提高其临床应用的特异性。
